Clinical  	Clinical  	 JJ	B-NP
roundtable  	roundtable  	 JJ	I-NP
monograph 	monograph 	 NN	I-NP
:  	:  	 :	O
Emerging  	Emerging  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	I-NP
TKI-resistant  	TKI-resistant  	 JJ	I-NP
chronic  	chronic  	 JJ	I-NP
myelogenous  	myelogenous  	 NNS	I-NP
leukemia  	leukemia  	 VBP	I-NP
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
tyrosine  	tyrosine  	 FW	B-NP
kinase  	kinase  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
TKIs 	TKIs 	 NNP	B-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
inhibit  	inhibit  	 VBP	O
signaling  	signaling  	 VBG	O
of  	of  	 IN	O
the  	the  	 DT	O
constitutive  	constitutive  	 JJ	B-NP
BCR-ABL  	BCR-ABL  	 JJ	I-NP
protein  	protein  	 NN	I-NP
revolutionized  	revolutionized  	 VBD	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
myelogenous  	myelogenous  	 JJ	I-NP
leukemia  	leukemia  	 NN	I-NP
( 	( 	 -LRB-	O
CML 	CML 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
agents  	agents  	 NNS	O
have  	have  	 VBP	O
dramatically  	dramatically  	 RB	O
changed  	changed  	 VBN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	B-NP
landscape  	landscape  	 NN	I-NP
for  	for  	 IN	O
CML 	CML 	 NNP	O
,  	,  	 ,	O
shifting  	shifting  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
allogeneic  	allogeneic  	 JJ	B-NP
stem  	stem  	 NN	I-NP
cell  	cell  	 NN	I-NP
transplantation  	transplantation  	 NN	I-NP
to  	to  	 TO	O
selected  	selected  	 JJ	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
salvage  	salvage  	 NN	B-NP
setting 	setting 	 NN	I-NP
.  	.  	 .	O
Four  	Four  	 CD	O
BCR-ABL  	BCR-ABL  	 JJ	B-NP
TKIs  	TKIs  	 NNS	I-NP
are  	are  	 VBP	O
now  	now  	 RB	O
commercially  	commercially  	 RB	O
available  	available  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
CML 	CML 	 NNP	O
:  	:  	 :	O
the  	the  	 DT	O
first-generation  	first-generation  	 JJ	B-NP
TKI  	TKI  	 NNP	I-NP
imatinib 	imatinib 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
second-generation  	second-generation  	 JJ	B-NP
TKIs  	TKIs  	 JJ	I-NP
dasatinib 	dasatinib 	 NN	I-NP
,  	,  	 ,	O
nilotinib 	nilotinib 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
bosutinib 	bosutinib 	 NN	B-NP
.  	.  	 .	O
Continuous  	Continuous  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
induces  	induces  	 VBZ	O
durable  	durable  	 JJ	O
responses  	responses  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
high  	high  	 JJ	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic-phase  	chronic-phase  	 NNP	B-NP
CML 	CML 	 NNP	I-NP
.  	.  	 .	O
Research  	Research  	 NNP	O
is  	is  	 VBZ	O
focused  	focused  	 VBN	O
on  	on  	 IN	O
identifying  	identifying  	 NNS	O
which  	which  	 WDT	O
patients  	patients  	 NNS	O
can  	can  	 MD	O
discontinue  	discontinue  	 VB	O
therapy  	therapy  	 NN	O
without  	without  	 IN	O
a  	a  	 DT	O
recurrence  	recurrence  	 NN	O
of  	of  	 IN	O
disease 	disease 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
resistance  	resistance  	 NN	O
to  	to  	 TO	O
TKIs 	TKIs 	 JJ	O
,  	,  	 ,	O
multiple  	multiple  	 JJ	O
alternative  	alternative  	 NN	B-NP
therapies  	therapies  	 NNS	I-NP
are  	are  	 VBP	O
being  	being  	 VBG	O
evaluated 	evaluated 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
third-generation  	third-generation  	 JJ	B-NP
TKI  	TKI  	 NNP	I-NP
ponatinib  	ponatinib  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
BCR-ABL  	BCR-ABL  	 JJ	B-NP
inhibitor  	inhibitor  	 NN	I-NP
that  	that  	 WDT	O
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
significant  	significant  	 JJ	O
activity 	activity 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
the  	the  	 DT	O
TKI  	TKI  	 NNP	O
resistance  	resistance  	 NN	O
mutation  	mutation  	 NN	O
T315I 	T315I 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
homoharringtonine  	homoharringtonine  	 JJ	B-NP
derivative  	derivative  	 JJ	I-NP
omacetaxine  	omacetaxine  	 JJ	I-NP
mepesuccinate 	mepesuccinate 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
inhibits  	inhibits  	 VBZ	O
protein  	protein  	 JJ	B-NP
synthesis 	synthesis 	 NN	I-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
also  	also  	 RB	O
demonstrated  	demonstrated  	 VBN	O
clinical  	clinical  	 JJ	B-NP
activity  	activity  	 NN	I-NP
in  	in  	 IN	O
CML 	CML 	 NNP	O
,  	,  	 ,	O
including  	including  	 VBG	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
TKI  	TKI  	 NNP	B-NP
resistance  	resistance  	 NN	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
T315I  	T315I  	 CD	O
and  	and  	 CC	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
have  	have  	 VBP	O
TKI  	TKI  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
despite  	despite  	 IN	O
no  	no  	 DT	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
ABL  	ABL  	 NNP	B-NP
mutations 	mutations 	 NNS	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
essential  	essential  	 JJ	O
that  	that  	 IN	O
clinicians  	clinicians  	 RB	O
implement  	implement  	 VB	O
these  	these  	 DT	O
new  	new  	 JJ	O
agents  	agents  	 NNS	O
with  	with  	 IN	O
care  	care  	 NN	O
and  	and  	 CC	O
change  	change  	 NN	B-NP
therapies  	therapies  	 NNS	I-NP
only  	only  	 RB	O
when  	when  	 WRB	O
appropriate  	appropriate  	 JJ	O
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
preserve  	preserve  	 VB	O
as  	as  	 IN	O
many  	many  	 JJ	O
options  	options  	 NNS	O
as  	as  	 IN	O
possible  	possible  	 JJ	O
for  	for  	 IN	O
future  	future  	 JJ	O
use  	use  	 NN	O
if  	if  	 IN	O
needed 	needed 	 VBN	O
.  	.  	 .	O
